NASDAQ:ALEC - US0144421072 - Common Stock
We assign a fundamental rating of 3 out of 10 to ALEC. ALEC was compared to 547 industry peers in the Biotechnology industry. Both the profitability and financial health of ALEC have multiple concerns. ALEC is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -32.35% | ||
ROE | -161.98% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.13 | ||
Debt/FCF | N/A | ||
Altman-Z | -3.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.78 | ||
Quick Ratio | 3.78 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
2.39
-0.01 (-0.42%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 2.98 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 3.4 | ||
P/tB | 3.4 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -32.35% | ||
ROE | -161.98% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.13 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 3.75% | ||
Cap/Sales | 0.51% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.78 | ||
Quick Ratio | 3.78 | ||
Altman-Z | -3.23 |